William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating on October 21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors that highlight Viking Therapeutics’ promising developments. The company has initiated a Phase I maintenance dosing study of VK2735 in adults with obesity, which is a significant step forward in their clinical trials. This study will explore various dosing regimens, including both oral and subcutaneous options, indicating a comprehensive approach to treatment.
Additionally, the rapid enrollment pace in the Phase III VANQUISH-1 trial underscores the strong interest and enthusiasm from both patients and physicians for Viking’s obesity treatment programs. The company is also planning to have an end-of-Phase-II meeting with the FDA by the end of the year to discuss the next steps for the oral VK2735 program, further demonstrating their proactive strategy in advancing their pipeline.
In another report released on October 21, Maxim Group also reiterated a Buy rating on the stock with a $70.00 price target.